Boxer Capital Management LLC Takes $17.10 Million Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Boxer Capital Management LLC purchased a new stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 425,000 shares of the company's stock, valued at approximately $17,098,000. Kymera Therapeutics makes up 1.4% of Boxer Capital Management LLC's investment portfolio, making the stock its 22nd largest holding. Boxer Capital Management LLC owned 0.66% of Kymera Therapeutics at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of KYMR. Blue Trust Inc. lifted its stake in shares of Kymera Therapeutics by 74.8% during the fourth quarter. Blue Trust Inc. now owns 631 shares of the company's stock valued at $25,000 after acquiring an additional 270 shares during the period. KBC Group NV grew its position in shares of Kymera Therapeutics by 53.8% during the 4th quarter. KBC Group NV now owns 2,151 shares of the company's stock worth $87,000 after buying an additional 752 shares during the period. Tower Research Capital LLC TRC increased its stake in shares of Kymera Therapeutics by 95.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,812 shares of the company's stock valued at $194,000 after acquiring an additional 2,350 shares during the last quarter. Summit Investment Advisors Inc. raised its position in shares of Kymera Therapeutics by 9.0% in the 4th quarter. Summit Investment Advisors Inc. now owns 4,912 shares of the company's stock valued at $198,000 after acquiring an additional 406 shares during the period. Finally, BI Asset Management Fondsmaeglerselskab A S acquired a new position in Kymera Therapeutics during the fourth quarter valued at approximately $251,000.

Analyst Ratings Changes

A number of analysts recently commented on KYMR shares. Citigroup initiated coverage on shares of Kymera Therapeutics in a research report on Thursday, March 13th. They issued a "buy" rating and a $52.00 price objective for the company. Stephens reiterated an "overweight" rating and set a $60.00 price objective on shares of Kymera Therapeutics in a report on Tuesday, January 21st. Finally, HC Wainwright boosted their price target on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the stock a "buy" rating in a research report on Friday, February 28th. Three research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, Kymera Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $56.36.

Kymera Therapeutics Stock Performance

Shares of Kymera Therapeutics stock traded up $0.91 on Wednesday, hitting $29.48. The stock had a trading volume of 201,775 shares, compared to its average volume of 559,829. The firm has a market capitalization of $1.92 billion, a P/E ratio of -12.58 and a beta of 2.18. The stock has a 50 day moving average of $29.61 and a 200 day moving average of $37.97. Kymera Therapeutics, Inc. has a twelve month low of $19.45 and a twelve month high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.12). Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The company had revenue of $7.39 million for the quarter, compared to analyst estimates of $14.81 million. Equities analysts expect that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Insider Activity at Kymera Therapeutics

In related news, CFO Bruce N. Jacobs sold 7,035 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $214,215.75. Following the transaction, the chief financial officer now owns 201,886 shares in the company, valued at $6,147,428.70. The trade was a 3.37 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Ellen Chiniara sold 2,241 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $68,238.45. Following the sale, the insider now owns 80,085 shares of the company's stock, valued at approximately $2,438,588.25. The trade was a 2.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 10,659 shares of company stock worth $324,567 over the last ninety days. Insiders own 15.82% of the company's stock.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.